John Patrick Shannon Jr. - 01 Aug 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Executive Officer and Director, Director
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
01 Aug 2025
Net transactions value
-$198,619
Form type
4
Filing time
04 Aug 2025, 16:24:53 UTC
Previous filing
03 Feb 2025
Next filing
17 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shannon John Patrick Jr Chief Executive Officer and Director, Director C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO /s/ Beth Hecht, Attorney-in-Fact 04 Aug 2025 0001553595

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability $198,619 -36,918 -1.4% $5.38 2,657,425 01 Aug 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2025.
F2 These shares include 7,225 shares that were purchased on June 30, 2025, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan

Remarks:

Chief Executive Officer and Director